Work

Intravitreal faricimab for refractory macular edema associated with uveitis-glaucoma-hyphema syndrome: a report of two cases

Year: 2026

Type: article

Abstract: Purpose To report the anatomical and functional outcomes of intravitreal faricimab in two cases of persistent cystoid macular edema (CME) associated with uveitis–glaucoma–hyphema (UGH) syndrome. Case description Two patients with UGH syndrome developed persistent CME refractory to conventional medical treatment. Both patients had a history of three-piece intraocular lens implantation in the sulcus and demonstrated findings suggestive of mechanical iris chafing in the absence of associated retinal vascular pathology. Initial treatment with topical nonsteroidal anti-inflammatory drugs, topical corticosteroids, and periocular corticosteroid injections failed to achieve anatomical resolution of CME. Intravitreal corticosteroid therapy was considered but avoided because of coexisting glaucoma and concerns regarding intraocular pressure elevation. Both patients subsequently received a single intravitreal injection of faricimab, resulting in resolution of CME and improvement in visual acuity, with sustained anatomical stability during follow-up. Conclusion Intravitreal faricimab demonstrated favorable anatomical and functional outcomes in two patients with refractory CME secondary to UGH syndrome. These findings suggest that faricimab may serve as an alternative treatment strategy in selected cases where conventional therapeutic options are limited.

Source: Journal of Ophthalmic Inflammation and Infection

DOI: 10.1186/s12348-026-00633-7